Preclinical Efficacy of a Hemostatic Agent in Overcoming Dual Antiplatelet Therapy.

This preclinical evaluation of a prohemostatic agent involved patients who received aspirin and clopidogrel before coronary artery stenting, the use of a humanized animal model to assess the hemostatic properties of patient platelets, as well as microfluidic assays to measure platelet reactivity. We demonstrate that our investigational product can bypass the effects of dual antiplatelet therapy (DAPT) by generating thrombin at sites of vascular injury, thereby restoring the hemostatic properties of patient platelets. Importantly, its effects could be reversed upon administration of a thrombin inhibitor.

Characterization of a canine freeze-dried platelet-derived hemostatic agent: A preclinical model for surgical and traumatic hemorrhage.

Introduction: A freeze-dried, platelet-derived hemostatic agent (FPH) was developed for acute hemorrhage. The canine product (cFPH) was developed for use in preclinical models supporting human product (hFPH) investigations.

Materials And Methods: A carotid artery bypass graft (CABG) study in dogs compared 3 dosages of cFPH to canine liquid stored platelets (cLSP) and vehicle (VEH) control groups.

Mechanisms of action of an investigational new freeze-dried platelet-derived hemostatic product.

Background: A safe and efficacious hemostatic product with a long shelf-life is needed to reduce mortality from hemorrhage due to trauma and improve surgical outcomes for persons with platelet deficiency or dysfunction. Thrombosomes, a trehalose-stabilized, leukoreduced, pooled blood group-O freeze-dried platelet-derived hemostatic (FPH) with a 3-year shelf-life, may satisfy this need.

Objectives: To characterize the mechanism of action of FPH.

Pilot study of frozen platelet extracellular vesicles as a therapeutic agent in hemorrhagic shock in rats.

Background: Hemorrhage accounts for the most preventable deaths after trauma. Resuscitation is guided by studies that demonstrate improved outcomes in patients receiving whole blood or balanced administration of blood products. Platelets present a logistical challenge due to short shelf life and need for refrigeration.

In Vitro Treatment of Extracorporeal Membrane Oxygenation Coagulopathy with Recombinant von Willebrand Factor or Lyophilized Platelets.

Objectives: The objective was to compare primary hemostasis between adult ECMO patients and cardiac surgical patients before heparinization and cardiopulmonary bypass. Furthermore, the authors explored whether in vitro treatment of ECMO patient blood samples with recombinant von Willebrand Factor (vWF) or lyophilized platelets improved primary hemostasis in vitro.

Design: Prospective cohort study.